Baotou Dongbao Bio-Tech Co.,Ltd (SHE:300239)
China · Delayed Price · Currency is CNY 6.11
-0.02 (-0.33%)
At close: Feb 27, 2026
SHE:300239 Revenue
Baotou Dongbao Bio-Tech Co.,Ltd had revenue of 163.74M CNY in the quarter ending September 30, 2025, a decrease of -13.29%. This brings the company's revenue in the last twelve months to 784.62M, down -10.12% year-over-year. In the year 2024, Baotou Dongbao Bio-Tech Co.,Ltd had annual revenue of 884.93M, down -9.19%.
Revenue (ttm)
784.62M
Revenue Growth
-10.12%
P/S Ratio
4.54
Revenue / Employee
566.51K
Employees
1,385
Market Cap
3.56B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 884.93M | -89.58M | -9.19% |
| Dec 31, 2023 | 974.51M | 31.12M | 3.30% |
| Jan 1, 2023 | 943.40M | 331.23M | 54.11% |
| Jan 1, 2022 | 612.17M | 163.34M | 36.39% |
| Dec 31, 2020 | 448.83M | -43.26M | -8.79% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| PKU HealthCare Corp.,Ltd. | 1.76B |
| Nanjing Well Pharmaceutical Group | 1.31B |
| Hunan Hansen Pharmaceutical | 1.05B |
| Anhui Sunhere Pharmaceutical Excipients | 934.72M |
| Harbin Medisan Pharmaceutical | 874.60M |
| Zhejiang Shengda Bio-Pharm | 839.82M |
| Jiangxi Synergy Pharmaceutical | 825.20M |
| Zhejiang Cheng Yi Pharmaceutical | 790.86M |